Method and Composition for Detecting Dihydropyrimidine Dehydrogenase Splicing Mutations
Description of Invention:
Dihydropyrimidine dehydrogenase (DPD) is the first and rate limiting enzyme in the three step metabolic pathway of the catabolism of thymidine and uracil. In mammals, this pathway is the route for synthesis of beta-alanine. DPD can be considered an enzyme that is expressed in most cells, but has been studied extensively in liver, lymphocytes, and the CNS. DPD is responsible for the metabolism of fluoropyrimidine drugs, such as the much used chemotherapeutic agent 5-fluorouracil.
The invention covers isolated nucleic acids that code for DP. It also includes nucleic acids that code for a DPD polypeptide that specifically binds to an antibody generated against an immunogen consisting of DPD polypeptide and its amino acid sequence. Also claimed are methods for determining whether a cancer patient is at risk of a toxic reaction to 5-fluorouracil. The methods involve analyzing DPD DNA or mRNA a sample from the patient to determine the amount of intact DPD nucleic acid.
Inventors:
Frank J. Gonzalez Pedro Fernandez-Salguero (NCI)
Patent Status:
DHHS Reference No. E-157-94/1 filed 20 Mar 1996
Portfolios: Internal Medicine Cancer
Cancer -Therapeutics-Conventional Chemotherapy Cancer -Research Materials-DNA Based Cancer -Diagnostics Cancer -Therapeutics Cancer -Research Materials Internal Medicine-Diagnostics
For Additional Information Please Contact: Mojdeh Bahar J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-2950
Email: baharm@mail.nih.gov
Fax: (301) 402-0220
